argenx to Host Conference Call & Webcast to Report
Post# of 301275
8 March 2017 Breda, the Netherlands / Ghent, Belgium - argenx (Euronext Brussels: ARGX), a clinical-stage biotechnology company developing a deep pipeline of differentiated antibody-based therapies for the treatment of severe autoimmune diseases and cancer, today announced it will host a conference call and audio webcast on Wednesday, March 15, 2017 at 3:00 pm CET (10:00 am EDT) to discuss the 2016 financial results, as well as provide a fourth quarter business update.
To participate in the conference call, please select your phone number below, and use the confirmation code 75576807. The webcast may be accessed on the homepage of the argenx website at www.argenx.com or by clicking here .
A replay of the webcast will also be available on the argenx website .
About argenx argenx a clinical-stage biotechnology company with a deep pipeline of differentiated antibody-based therapies intended for the treatment of severe auto-immune diseases and cancer. We are focused on developing product candidates that are either first-in-class against novel targets or best-in-class against known, but complex, targets to treat diseases with a significant unmet medical need. Our ability to execute on this focus is enabled by our suite of differentiated technologies. Our SIMPLE Antibody TM Platform, based on the powerful llama immune system, allows us to exploit novel and complex targets, and our three antibody engineering technologies enable us to expand the therapeutic index of our product candidates. www.argenx.com
Dial-In Numbers:
Participant Free Call Dial-In Numbers: UK 0800 694 0257
Participant Standard International Dial-In: UK Standard International +44 (0) 1452 555 566
Participant UK Local Call Dial-In Numbers: UK 0844 493 3800 UK National Call 0871 700 0345
Participant Local Call Dial-In Numbers: Australia 0290 371 687 Austria 0192 865 68 Belgium 0817 000 61 Croatia 0177 766 11 Czech Republic 2288 804 60 Denmark 3272 7625 Finland 0923 195 187 France 0176 742 428 Germany 0692 222 3479 Germany 0692 222 4918 Hungary 0618 088 303 India 0223 098 5304 Ireland 0143 196 48 Ireland 0150 601 53 Italy 0236 008 146 Latvia 6778 2516 Luxembourg 2088 0695 Netherlands 0207 176 886 New Zealand 0992 917 07 Norway 2156 3013 Poland 2230 701 18 Romania 0318 144 957 Russia 4996 771 036 Slovenia 0160 093 64 South Africa 2110 032 02 Spain 9141 436 69 Sweden 0850 336 434 Switzerland 0565 800 007 USA 1631 510 7498
For further information, please contact:
Joke Comijn, Corporate Communications Manager +32 (0)477 77 29 44 +32 (0)9 243 40 70 info@argenx.com
Beth DelGiacco (US IR) Stern Investor Relations +1 212 362 1200 beth@sternir.com
Forward-looking Statements
The contents of this announcement include statements that are, or may be deemed to be, "forward-looking statements". These forward-looking statements can be identified by the use of forward-looking terminology, including the terms "believes", "estimates", "anticipates", "expects", "intends", "may", "will", or "should", and include statements argenx makes concerning the intended results of its strategy. By their nature, forward-looking statements involve risks and uncertainties and readers are cautioned that any such forward-looking statements are not guarantees of future performance. argenx' actual results may differ materially from those predicted by the forward-looking statements. argenx undertakes no obligation to publicly update or revise forward-looking statements, except as may be required by law. "Management's Discussion and Analysis of Financial Condition and Results of Operations"
(0)
(0)